

**34th EDRN Steering Committee Meeting and  
6th Annual US Japan Workshop on Cancer Biomarkers  
in Collaboration with NCI Early Detection Research  
Network**

**March 18-20, 2019  
Hilton Garden Inn, Downtown  
Nashville, Tennessee**

**Breast and Gynecological Cancers  
Collaborative Group Meeting**

**Wednesday March 20, 2019  
8:00 a.m. – 12:05 p.m.**

**Room: 12-South**

**Chair:**

Steven Skates, Ph.D., Massachusetts General Hospital

**Co-Chair:**

Christopher Li, M.D., Ph.D., Fred Hutchinson Cancer Research Center

**NCI Program Directors:**

Christos Patriotis, Ph.D. and Sharmistha Ghosh-Janjigian, Ph.D., National Cancer Institute

**Agenda**

**7:00 a.m. – 8:00 a.m. Sign-In and Continental Breakfast**

8:00 a.m. – 8:10 a.m.

Welcome

- Steven Skates, Ph.D., Massachusetts General Hospital
- Christos Patriotis, Ph.D., National Cancer Institute

**Each Site should include/respond to the following questions as a “self-evaluation” for their specific group:**

**Are there any biomarkers for breast or ovarian cancer that are ready for validation? Rank them in terms of their readiness (Phase 1, Phase 2 or Phase 3) for validation. Then answer the following:**

- 1. What is the intended use, e.g., screening; clinical decision of biopsy; repeat biopsy, etc.**
- 2. What is the type of marker or biomarker panel?**
- 3. What is the type(s) of specimens (tissue, blood and or urine)?**
- 4. How does the new biomarker or the new panel of biomarkers add to the current knowledge baseline?**
- 5. What are the parameters of sensitivity, specificity, PPV, NPV, AUC and how does this compare to the current standard of care?**

**34th EDRN Steering Committee Meeting and  
6th Annual US Japan Workshop on Cancer Biomarkers  
in Collaboration with NCI Early Detection Research  
Network**

**March 18-20, 2019  
Hilton Garden Inn, Downtown  
Nashville, Tennessee**

**Breast and Gynecological Cancers  
Collaborative Group Meeting**

<b>8:10 a.m. – 11:20 a.m.</b>	<b>Individual Site Updates</b>
<i>8:10 a.m. – 8:25 a.m.</i>	<u>ASU Breast Cancer BDL</u> <ul style="list-style-type: none"><li>○ Joshua LaBaer, M.D., Ph.D., Arizona State University/The Biodesign Institute</li><li>○ Karen Anderson, M.D., Ph.D., Arizona State University/The Biodesign Institute</li></ul>
<i>8:25 a.m. – 8:30 a.m.</i>	Q&A
<i>8:30 a.m. – 8:45 a.m.</i>	<u>Duke Breast Cancer BDL</u> <ul style="list-style-type: none"><li>○ Jeffrey Marks, Ph.D., Duke University Medical Center</li><li>○ Cha-Mei Tang, Sc.D., Creatv MicroTech, Inc.</li></ul>
<i>8:45 a.m. – 8:50 a.m.</i>	Q&A
<i>8:50 a.m. – 9:05 a.m.</i>	<u>Unique Approach Combining Avatar Mice and Targeted Mass Spectrometry to Identify Blood Biomarkers for Early Detection of Breast Cancer</u> <ul style="list-style-type: none"><li>○ Amanda Paulovich, M.D., Ph.D., Fred Hutchinson Cancer Research Center</li><li>○ Michael Lewis, Ph.D., Baylor College of Medicine</li></ul>
<i>9:05 a.m. – 9:10 a.m.</i>	Q&A
<i>9:10 a.m. – 9:20 a.m.</i>	<u>FHCRC Breast/Ovarian/Colon CVC</u> Christopher Li, M.D., Ph.D., Fred Hutchinson Cancer Research Center

**34th EDRN Steering Committee Meeting and  
6th Annual US Japan Workshop on Cancer Biomarkers  
in Collaboration with NCI Early Detection Research  
Network**

**March 18-20, 2019  
Hilton Garden Inn, Downtown  
Nashville, Tennessee**

**Breast and Gynecological Cancers  
Collaborative Group Meeting**

**Individual Site Updates (Continued)**

<i>9:20 a.m. – 9:30 a.m.</i>	<u>Identification of Biomarkers for Non-triple Negative Breast Cancer</u> Christopher Li, M.D., Ph.D., Fred Hutchinson Cancer Research Center
<i>9:30 a.m. – 9:35 a.m.</i>	Q&A
<i>9:35 a.m. – 9:50 a.m.</i>	<u>H. Lee Moffitt Cancer Center CVC Breast Imaging</u> John Heine, Ph.D., H. Lee Moffitt Cancer Center and Research Institute, Inc.
<i>9:50 a.m. – 9:55 a.m.</i>	Q&A
<b>9:55 a.m. – 10:05 a.m.</b>	<b>Break</b>
<i>10:05 a.m. – 10:20 a.m.</i>	<u>Validation of Biomarkers for Early Detection of Ovarian Cancer: An Update</u> Robert Bast, M.D., The University of Texas MD Anderson Cancer Center
<i>10:20 a.m. – 10:25 a.m.</i>	Q&A
<i>10:25 a.m. – 10:35 a.m.</i>	<u>FHCRC Breast/Ovarian/Colon CVC</u> Charles Drescher, M.D., Fred Hutchinson Cancer Research Center
<i>10:35 a.m. – 10:40 a.m.</i>	Q&A
<i>10:40 a.m. – 10:55 a.m.</i>	<u>MGH Ovarian Cancer BDL</u> Steven Skates, Ph.D., Massachusetts General Hospital
<i>10:55 a.m. – 11:00 a.m.</i>	Q&A

**34th EDRN Steering Committee Meeting and  
6th Annual US Japan Workshop on Cancer Biomarkers  
in Collaboration with NCI Early Detection Research  
Network**

**March 18-20, 2019  
Hilton Garden Inn, Downtown  
Nashville, Tennessee**

**Breast and Gynecological Cancers  
Collaborative Group Meeting**

**Individual Site Updates (Continued)**

<i>11:00 a.m. – 11:15 a.m.</i>	<u>JHU Ovarian Cancer BDL</u> <ul style="list-style-type: none"><li>○ Zhen Zhang, Ph.D., Johns Hopkins University School of Medicine</li><li>○ Ie-Ming Shih, M.D., Ph.D., Johns Hopkins Medical Institutions</li></ul>
<i>11:15 a.m. – 11:20 a.m.</i>	Q&A
<b>11:20 a.m. – 12:05 p.m.</b>	<b>Collaborative Project Updates</b>
<i>11:20 a.m. – 11:30 p.m.</i>	<u>Imaging Plus Biomarkers for the Diagnosis of Breast Cancer</u> <ul style="list-style-type: none"><li>○ Jeffrey Marks, Ph.D., Duke University Medical Center</li><li>○ John Heine, Ph.D., H. Lee Moffitt Cancer Center and Research Institute, Inc.</li></ul>
<i>11:30 a.m. – 11:35 a.m.</i>	Q&A
<i>11:35 p.m. – 11:45 p.m.</i>	<u>Circulating Autoantibody Biomarkers for Early Detection of Ovarian Cancer</u> Robert Bast, M.D., The University of Texas MD Anderson Cancer Center
<i>11:45 a.m. – 11:50 a.m.</i>	Q&A
<i>11:50 a.m. – 12:00 p.m.</i>	<u>Uterine Lavage tDNA and Serum Protein Biomarkers in Early Detection of Ovarian Cancer</u> Steven Skates, Ph.D., Massachusetts General Hospital
<i>12:00 a.m. – 12:05 p.m.</i>	Q&A
<b>12:05 p.m.</b>	<b>Adjourn</b>